Latest Cann (ASX:CAN) News

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.

Cann Group’s CEO Jenni Pilcher steps down after leading a dramatic debt reduction and cost overhaul. Chairman Mike Ryan takes interim charge as the company hunts for a new CEO.

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.

Cann Group Limited has raised $750,000 through a convertible note agreement with Obsidian Global, aiming to strengthen its working capital and move towards EBITDA positivity.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Cann Group Limited has reported its first-ever free cash flow positive quarter, following a significant debt restructuring and a $9 million capital raise. Despite a softer quarterly revenue, the company is advancing new product launches and export partnerships, positioning itself for growth.

Cann Group Limited has launched a comprehensive suite of option offers aimed at raising incremental capital, subject to shareholder approval at a December 23 meeting. The prospectus outlines potential dilution and financial impacts as the company seeks to strengthen its balance sheet.

Cann Group Limited has successfully completed a significant debt restructure and equity raising, improving its financial footing and liquidity to support future growth.

Cann Group Limited has announced a dramatic 81% reduction in core debt alongside a strategic pivot to higher-margin flower products, positioning the company for its first EBITDA-positive year in FY26.

Cann Group Limited has successfully restructured its debt, stabilizing its finances and boosting operational performance, while appointing Mike Ryan as its new Chairman to guide future growth.

Cann Group Limited has successfully raised an additional $2.5 million through a Share Purchase Plan and shortfall placement, complementing a prior $6.5 million institutional placement. These funds will primarily support debt repayment and strengthen the company’s financial position.

Cann Group Limited reminds eligible shareholders that its Share Purchase Plan (SPP) closes today, offering new shares at a discount plus free attaching options, pending shareholder approval.